Asia

Pharma

Merck-Kelun, China deal wisdom, Takeda—Fierce Pharma Asia

Merck and Kelun's sac-TMT reported three positive phase 3s. Experts talk useful tools in China dealmaking. Takeda was hit with a pay-for-delay verdict.

Angus Liu May 22, 2026 8:53am

ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS

May 21, 2026 5:00pm

Novartis in plant contract dispute with Chinese CDMO Porton

May 18, 2026 4:27pm

In endometrial cancer, Merck and Kelun score with sac-TMT

May 18, 2026 11:21am

BMS-Hengrui, Takeda layoffs, Daiichi—Fierce Pharma Asia

May 15, 2026 8:30am

The curious absence of pharma CEOs on Trump’s China trip

May 13, 2026 2:25pm